The DOI matches its Crossref record.
Etiopathogenesis of Nonalcoholic Steatohepatitis
Abstract
The definable causes of nonalcoholic steatohepatitis (NASH) include jejunoileal bypass surgery (JIB), other causes of rapid and profound weight loss in obese subjects, total parenteral nutrition, drugs, industrial toxins, copper toxicity, and disorders characterized by extreme insulin resistance. However, the etiopathogenesis in most cases of NASH appears multifactorial. Obesity, type 2 diabetes, and hypertriglyceridemia are often associated with hepatic steatosis, and although this does not invariably lead to NASH, the fatty liver is vulnerable to hepatocellular injury initiated by reactive oxygen species (ROS). It is critical to understand not only the triggers for hepatitis (injury and inflammation) in NASH but also how this is perpetuated as chronic liver disease. The present focus is on whether the biochemical processes that generate oxidative stress lead to hepatocyte injury and secondary recruitment of inflammation or whether inflammation is the primary mediator of liver cell injury. Insulin resistance is a reproducible pathogenic factor in NASH. It favors accumulation of free fatty acids in the liver and predisposes to oxidative stress by stimulating microsomal lipid peroxidases and by the direct effects of high insulin levels in decreasing mitochondrial beta-oxidation. CYP2E1 is normally suppressed by insulin but is invariably increased in the livers of patients with NASH. In rodent dietary models of steatohepatitis, CYP2E1 is the catalyst of microsomal lipid peroxidation, while in Cyp 2e1 nullizygous mice, CYP4A proteins are induced and function as alternative microsomal lipid peroxidases. Other studies implicate activation of peroxisome proliferator-activated receptor-alpha (PPAR alpha) as leading to NASH; PPAR alpha is a transcription factor that governs both microsomal (via CYP4A) and peroxisomal (beta-oxidation) pathways of lipid oxidation and ultimately production of ROS. Increased lipid peroxidation is a crucial difference between the livers of rodents with experimental NASH and those of ob/ob genetically obese mice that have uncomplicated steatosis. Administration of endotoxin, through the release of tumor necrosis factor-alpha (TNF-alpha), provokes liver inflammation with hepatocyte injury in the steatotic liver. This may be particularly relevant in JIB and has been suggested as a pathogenic mechanism in primary NASH. It has been proposed that inheriting one or more copies of the hemochromatosis gene, C282Y, promotes fibrotic progression in NASH because of increased hepatic iron deposition, but recent studies have failed to confirm this. The relationship between the severity of hepatitis in NASH and progression to cirrhosis implies that products of the inflammatory infiltrate play a role in fibrogenesis. In summary, NASH can be regarded as the hepatic consequence of the metabolic syndrome (or syndrome X). Attention should now shift from steatosis, a generally benign process that is less evident in the advanced stages of cirrhosis, to the mechanisms for hepatocellular injury, inflammation, and hepatic fibrosis. In particular, the genetic, molecular, and cellular factors that ordain and moderate fibrosis in the context of steatohepatitis will be of greatest relevance to effective therapy and clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Self-citationNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Self-citationXu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00980-1 · Cited by 897
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 856
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.
Pérez-Carreras, M., Del Hoyo, P., Martín, M. A., Rubio, J. C., Martín, A., Castellano, G., Colina, F., Arenas, J., & Solis-Herruzo, J. A. (2003) · Hepatology · doi:10.1002/hep.1840380426 · Cited by 734
Crespo, J., Cayón, A., Fernández-Gil, P., Hernández-Guerra, M., Mayorga, M., Domínguez-Díez, A., Fernández-Escalante, J. C., & Pons-Romero, F. (2001) · Hepatology · doi:10.1053/jhep.2001.29628 · Cited by 693
The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions
Li, L., & Yang, X. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/7580707 · Cited by 634
Burden of liver disease in the United States: Summary of a workshop
Kim, R. W., Brown, R. S., Terrault, N. A., & El-Serag, H. (2002) · Hepatology · doi:10.1053/jhep.2002.34734 · Cited by 589
Matsuzawa-Nagata, N., Takamura, T., Ando, H., Nakamura, S., Kurita, S., Misu, H., Ota, T., Yokoyama, M., Honda, M., Miyamoto, K.-I., et al. (2008) · Metabolism · doi:10.1016/j.metabol.2008.03.010 · Cited by 535
Farrell, G. C., Chitturi, S., Lau, G. K., Sollano, J. D., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05002.x · Cited by 517
Self-citationOxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease
Paradies, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14205 · Cited by 500
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin
Kamada, Y., Tamura, S., Kiso, S., Matsumoto, H., Saji, Y., Yoshida, Y., Fukui, K., Maeda, N., Nishizawa, H., Nagaretani, H., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.029 · Cited by 479
Fat quantification with IDEAL gradient echo imaging: Correction of bias from T1 and noise
Liu, C., McKenzie, C. A., Yu, H., Brittain, J. H., & Reeder, S. B. (2007) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21301 · Cited by 477
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476
Self-citationHeritability of Nonalcoholic Fatty Liver Disease
Schwimmer, J. B., Celedon, M. A., Lavine, J. E., Salem, R., Campbell, N., Schork, N. J., Shiehmorteza, M., Yokoo, T., Chavez, A., Middleton, M. S., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.050 · Cited by 466
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 457
Epidemiology and natural history of non-alcoholic fatty liver disease
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D., & Younossi, Z. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.012 · Cited by 433
Leptin is essential for the hepatic fibrogenic response to chronic liver injury
Leclercq, I. A., Farrell, G. C., Schriemer, R., & Robertson, G. R. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00102-2 · Cited by 407
Self-citationNASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. V., Gan, L., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 398
Self-citationSTEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?
Asselah, T., Rubbia-Brandt, L., Marcellin, P., & Negro, F. (2006) · Gut · doi:10.1136/gut.2005.069757 · Cited by 395
Ip, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
Self-citationMolecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Anderson, N., & Borlak, J. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00001 · Cited by 385
Non-alcoholic fatty liver disease: The diagnosis and management
El-Kader, S. M. A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i6.846 · Cited by 381
Kumar, D., Farrell, G. C., Fung, C., & George, J. (2002) · Hepatology · doi:10.1053/jhep.2002.36370 · Cited by 379
Self-citationChitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., & George, J. (2002) · Hepatology · doi:10.1053/jhep.2002.34738 · Cited by 362
Self-citationII. Cytochrome P-450 enzymes and oxidative stress
Robertson, G., Leclercq, I., & Farrell, G. C. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.5.g1135 · Cited by 358
Self-citationImajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341
“In fact, LPS has been reported to be the predominant cause of liver neutrophil infiltration in NASH patients (Chitturi and Farrell, 2001; Zhao et at., 2004).”
BackgroundIndependent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., Goodman, Z., & Younossi, Z. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.007 · Cited by 342
Rahman, K., Desai, C., Iyer, S. S., Thorn, N. E., Kumar, P., Liu, Y., Smith, T., Neish, A. S., Li, H., Tan, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.06.022 · Cited by 334
Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients
Ong, J. P., Elariny, H., Collantes, R., Younoszai, A., Chandhoke, V., Reines, H. D., Goodman, Z., & Younossi, Z. M. (2005) · Obesity Surgery · doi:10.1381/0960892053576820 · Cited by 322
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice
Feldstein, A. E., Canbay, A., Guicciardi, M. E., Higuchi, H., Bronk, S. F., & Gores, G. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00460-4 · Cited by 320
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314
Salgado, A. L. F. D. A., Carvalho, L. D., Oliveira, A. C., Santos, V. N. D., Vieira, J. G., & Parise, E. R. (2010) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032010000200009 · Cited by 315
“Insulin resistance has a central role in both steatosis installation and in its progression to more advanced forms of the disease as non-alcoholic steatohepatitis (NASH), what makes it the main pathogenic mechanism of NAFLD(9, 24).”
BackgroundUpdate on Nonalcoholic Fatty Liver Disease
McCullough, A. J. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200203000-00013 · Cited by 315
Hepatic steatosis in obese patients: clinical aspects and prognostic significance
Festi, D., Colecchia, A., Sacco, T., Bondi, M., Roda, E., & Marchesini, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00126.x · Cited by 312
Chitturi, S., Farrell, G. C., Hashimoto, E., Saibara, T., Lau, G. K., Sollano, J. D., & NAFLD, T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05001.x · Cited by 312
Self-citationHistological assessment of non‐alcoholic fatty liver disease
Hübscher, S. G. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02416.x · Cited by 292
Guerra Ruiz, A., Casafont, F., Crespo, J., Cayón, A., Mayorga, M., Estebanez, A., Fernadez-Escalante, J. C., & Pons-Romero, F. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9243-7 · Cited by 269
The ins and outs of mitochondrial dysfunction in NASH
Fromenty, B., Robin, M., Igoudjil, A., Mansouri, A., & Pessayre, D. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70098-8 · Cited by 266
Hepatic Microcirculation in Fatty Liver Disease
Farrell, G. C., Teoh, N. C., & Mccuskey, R. S. (2008) · The Anatomical Record · doi:10.1002/ar.20715 · Cited by 266
Self-citationBays, H. E., Tighe, A. P., Sadovsky, R., & Davidson, M. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.391 · Cited by 265
Velayudham, A., Dolganiuc, A., Ellis, M., Petrasek, J., Kodys, K., Mandrekar, P., & Szabo, G. (2009) · Hepatology · doi:10.1002/hep.22711 · Cited by 263
KIRSCH, R., CLARKSON, V., SHEPHARD, E. G., MARAIS, D. A., JAFFER, M. A., WOODBURNE, V. E., KIRSCH, R. E., & HALL, P. D. L. M. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03198.x · Cited by 262
Nonalcoholic fatty liver disease: An agenda for clinical research
Younossi, Z. M., Diehl, A. M., & Ong, J. P. (2002) · Hepatology · doi:10.1053/jhep.2002.32483 · Cited by 261
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease
Choi, S. S., & Diehl, A. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ff5e55 · Cited by 255
Facchini, F. S., Hua, N. W., & Stoohs, R. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.32403 · Cited by 233
Nonalcoholic fatty liver disease
Erickson, S. K. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800089-jlr200 · Cited by 194
“In addition to higher prevalence of NAFLD in patients with obesity, metabolic syndrome, and type 2 diabetes, NAFLD also can be induced by a variety of drugs and toxins (6).”
BackgroundResolution of nonalcoholic steatohepatits after gastric bypass surgery
Liu, X., Lazenby, A. J., Clements, R. H., Jhala, N., & Abrams, G. A. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9086-2 · Cited by 149
Gan, L., Chitturi, S., & Farrell, G. C. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/831536 · Cited by 135
“NASH is now conceptualized as part of a pathological spectrum of a fatty liver disorders caused by metabolic factors and referred to collectively as nonalcoholic fatty liver disease (NAFLD).”
Self-citationKohli, R., Pan, X., Malladi, P., Wainwright, M. S., & Whitington, P. F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701759200 · Cited by 67
García-Ruiz, I., Fernández-Moreira, D., Solís-Muñoz, P., Rodríguez-Juan, C., Díaz-Sanjuán, T., Muñoz-Yagüe, T., & Solís-Herruzo, J. A. (2010) · Journal of Proteome Research · doi:10.1021/pr9011427 · Cited by 46
Lee, J. S., Ward, W. O., Ren, H., Vallanat, B., Darlington, G. J., Han, E.-S., Laguna, J. C., DeFord, J. H., Papaconstantinou, J., Selman, C., et al. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.05.006 · Cited by 44
How effective are lifestyle changes in the prevention of type 2 diabetes mellitus?
Pi-Sunyer, F. X. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00287.x · Cited by 40
Chandrasekaran, K., Swaminathan, K., Kumar, S. M., Clemens, D. L., & Dey, A. (2012) · Integrative Biology · doi:10.1039/c2ib00155a · Cited by 18
Metadata
- Authors
- Chitturi, S., & Farrell, G. C.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 21
- Issue
- 01
- Pages
- 027-042
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W1982578021
- Cited by
- 661
- References
- 0
- FWCI
- 32.56
- Type
- journal article
- Language
- it
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.